Literature DB >> 2006657

Choice of drug treatment for elderly hypertensive patients.

K O'Malley1, J P Cox, E O'Brien.   

Abstract

It is generally agreed that moderate and severe hypertension in the elderly should be treated, but it is not clear which drug or drugs are most appropriate. Thiazide diuretics are inexpensive and effective, but they are associated with metabolic side effects that are becoming less acceptable as newer agents become available. Beta blockers are effective, but can be associated with central nervous system side effects and are often contraindicated by coexisting disease. Recently, attention has been focused on the newer agents, including calcium antagonists and angiotensin-converting enzyme inhibitors. The advantage of calcium antagonists is that they do not produce metabolic side effects. However, they are expensive and may cause vasodilatory side effects. The angiotensin-converting enzyme inhibitors are effective and relatively free of side effects and may be particularly useful for elderly hypertensive patients with congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006657     DOI: 10.1016/0002-9343(91)90433-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients.

Authors:  Evan L Thacker; Sebastian Schneeweiss
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Secondary hypertension. An overview of its causes and management.

Authors:  D H Streeten; G H Anderson
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 3.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S Salpeter; T Ormiston; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

4.  Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.

Authors:  Qingxia Du; Yongchang Sun; Ning Ding; Lijin Lu; Ying Chen
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.